Eaton Vance Management Biogen Inc. Transaction History

Eaton Vance Management

$67.5 Billion
Q3 2022

A detailed history of Eaton Vance Management transactions in Biogen Inc. stock. As of the latest transaction made, Eaton Vance Management holds 112,246 shares of BIIB stock, worth $19.5 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

112,246

Previous 110,936 1.18%

Holding current value

$19.5 Million

Previous $22.6 Million 32.46%

% of portfolio

0.04%

Previous 0.03%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $255,043 - $351,682	1,310 Added 1.18%	112,246 $30 Million
Q2 2022 Aug 15, 2022	SELL	$187.54 - $223.02 $738,157 - $877,806	-3,936 Reduced 3.43%	110,936 $22.6 Million
Q1 2022 May 16, 2022	SELL	$193.77 - $244.14 $3.79 Million - $4.78 Million	-19,582 Reduced 14.56%	114,872 $24.2 Million
Q4 2021 Feb 14, 2022	SELL	$223.92 - $287.77 $1.57 Million - $2.01 Million	-6,995 Reduced 4.95%	134,454 $31.9 Million
Q3 2021 Nov 15, 2021	SELL	$282.99 - $369.05 $6.24 Million - $8.14 Million	-22,065 Reduced 13.49%	141,449 $39.5 Million
Q2 2021 Aug 16, 2021	BUY	$259.0 - $414.71 $6,734 - $10,782	26 Added 0.02%	163,514 $56.6 Million
Q1 2021 May 17, 2021	BUY	$242.95 - $284.63 $350,819 - $411,005	1,444 Added 0.89%	163,488 $45.7 Million
Q4 2020 Feb 12, 2021	BUY	$236.26 - $355.63 $2.08 Million - $3.13 Million	8,802 Added 5.74%	162,044 $39.7 Million
Q3 2020 Nov 13, 2020	SELL	$264.77 - $305.71 $4.04 Million - $4.66 Million	-15,254 Reduced 9.05%	153,242 $43.5 Million
Q2 2020 Aug 13, 2020	SELL	$258.66 - $342.55 $1.34 Million - $1.77 Million	-5,174 Reduced 2.98%	168,496 $45.1 Million
Q1 2020 May 14, 2020	BUY	$268.85 - $341.04 $360,259 - $456,993	1,340 Added 0.78%	173,670 $54.9 Million
Q4 2019 Feb 11, 2020	BUY	$220.06 - $304.07 $310,284 - $428,738	1,410 Added 0.82%	172,330 $51.1 Million
Q3 2019 Nov 14, 2019	SELL	$217.44 - $243.88 $28.4 Million - $31.9 Million	-130,783 Reduced 43.35%	170,920 $39.8 Million
Q2 2019 Aug 16, 2019	SELL	$219.29 - $241.72 $1.38 Million - $1.52 Million	-6,273 Reduced 2.04%	301,703 $70.6 Million
Q1 2019 May 14, 2019	SELL	$216.71 - $338.96 $12.9 Million - $20.2 Million	-59,556 Reduced 16.2%	307,976 $72.8 Million
Q4 2018 Feb 07, 2019	SELL	$278.5 - $352.75 $22.6 Million - $28.6 Million	-81,109 Reduced 18.08%	367,532 $111 Million
Q3 2018 Nov 13, 2018	BUY	$293.51 - $383.83 $15,262 - $19,959	52 Added 0.01%	448,641 $159 Million
Q2 2018 Aug 10, 2018	BUY	$257.52 - $306.91 $19.6 Million - $23.4 Million	76,192 Added 20.46%	448,589 $130 Million
Q1 2018 May 07, 2018	SELL	$260.13 - $367.91 $14.6 Million - $20.7 Million	-56,205 Reduced 13.11%	372,397 $102 Million
Q4 2017 Feb 12, 2018	SELL	$307.64 - $344.58 $6.08 Million - $6.81 Million	-19,771 Reduced 4.41%	428,602 $137 Million
Q3 2017 Nov 13, 2017	BUY	$281.15 - $329.69 $126 Million - $148 Million	448,373	448,373 $140 Million

Others Institutions Holding BIIB

# of Institutions

1,018

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eaton Vance Management, based on Form 13F filings with the SEC.

News

Stay updated on Eaton Vance Management with notifications on news.

Account

Eaton Vance Management Biogen Inc. Transaction History